HENGRUI PHARMA - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

or completeness of this announcement, and expressly expressly disclaims any liability arising out of or in reliance upon the whole or any part of the contents of this announcement. assumes no responsibility for any losses caused by such content.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Jiangsu Hengrui Pharmaceutical Co., Ltd.

(a joint stock limited company incorporated in the People's Republic of China) (Stock code: 1276)

Overseas regulatory announcement

This announcement is made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

In accordance with the relevant laws and regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceutical Co., Ltd. (the "Company")

The Shanghai Stock Exchange website (www.sse.com.cn) published the following announcement. They are listed below for reference only.

By order of the board of directors Jiangsu Hengrui Pharmaceutical Co., Ltd. Chairman

Mr. Sun Piaoyang

Shanghai, China July 29, 2026

As at the date of this announcement, members of the Board of Directors include (i) Executive Directors Mr. Sun Piaoyang, Mr. Dai Hongbin, and Mr. Feng Jinu; Mr. Zhang Lianshan, Mr. Jiang Ningjun and Mr. Sun Jieping; (ii) Ms. Guo Congzhao, a non-executive director; and (iii)

Independent non-executive directors Mr. Lou Liguang, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Zhou Ji'en.

Securities code: 600276 Securities abbreviation: Hengrui Medicine Announcement number: Lin 2026-109

Jiangsu Suhengheng Rui Medical Pharmaceutical Co., Ltd.

Announcement on Obtaining the Approval Notice for Clinical Trial Approval of Drugs

The board of directors and all directors of the company guarantee that the contents of this announcement do not contain any false records or misleading statements.

or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its content.

Recently, Fujian Shengdi Medical, a subsidiary of Jiangsu Hengrui Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") Pharmaceutical Co., Ltd. has received the approval and issuance from the State Food and Drug Administration (hereinafter referred to as the "State Food and Drug Administration")

The "Drug Clinical Trial Approval Notice" for HRS5580 for injection will start clinical trials in the near future. Present general

The relevant information is announced as follows:

11. Basic information about drugs

Drug name: HRS5580 for injection Dosage form: injection

Application Matters: Clinical Trial

Acceptance number: CXHL2 600457

Approval conclusion: According to the "Drug Administration Law of the People's Republic of China" and relevant regulations, after review, 2026

HRS5580 for injection, which was accepted on April 17, 2019, complies with the relevant requirements for drug registration, and it is approved to carry out II phase clinical trials. Indications applied for: Prevention of postoperative nausea and vomiting, combined with palonosetron hydrochloride injection

For the prevention of postoperative nausea and vomiting.

22. Other conditions of drugs

HRS5580 for injection is a selective neurokinin-1 (NK-1) receptor antagonist that blocks

Blocks substance P from binding to NK-1 receptors and exerts a powerful antiemetic effect. This variety has high solubility and safety Differentiated advantages such as good quality and long-lasting effect. After inquiry, it was found that drugs with the same target are already on the market around the world, such as Heron’s

Aprepitant injection emulsion (APONVIE®) is a short-acting NK-1 antagonist, and no long-acting formulation has been approved.

Up to now, the cumulative R&D investment in HRS5580 related projects has been approximately 57.7 million yuan (unaudited).

33. Risk reminders

According to the laws and regulations related to drug registration in China, the drug will receive a drug clinical trial approval notice.

After the approval, clinical trials must be carried out and reviewed and approved by the State Food and Drug Administration before it can be produced and marketed. Medicines

The cycle from research and development, clinical trial approval to production is long and has many links. Drug research and development and launch are vulnerable to a variety of factors.

Due to the influence of some uncertain factors, investors are advised to make prudent decisions and pay attention to guarding against investment risks. The company will

Actively promote the above-mentioned research and development projects in accordance with relevant national regulations, and perform information disclosure on the subsequent progress of the projects in a timely manner. Obligation to reveal.

Announcement is hereby made.

Board of Directors of Jiangsu Hengrui Pharmaceutical Co., Ltd.

July 29, 2026